聚焦艾昆纬-加速药物开发:2020-2024年快速批准的见解(英)-2026。“Sub-10th percentile” durations: the ultra-rapid outliers— about the fastest 10% of programs.1 These cases approached development times of only ~3–4 years(from Phase I to approval), which is extraordinary and may be unique.
聚焦艾昆纬-加速药物开发:2020-2024年快速批准的见解(英)-2026。“Sub-10th percentile” durations: the ultra-rapid outliers— about the fastest 10% of programs.1 These cases approached development times of only ~3–4 years(from Phase I to approval), which is extraordinary and may be unique.
聚焦艾昆纬-加速药物开发:2020-2024年快速批准的见解(英)-2026。“Sub-10th percentile” durations: the ultra-rapid outliers— about the fastest 10% of programs.1 These cases approached development times of only ~3–4 years(from Phase I to approval), which is extraordinary and may be unique.
本报告由艾昆纬发布,发布于 2026 年。
覆盖 2026 年,全文共 17 页。
本报告为付费报告,可在资料宝站内下单后获取完整内容。
适合行业研究员、战略规划等读者参考。
重点分析了药物、艾昆纬、加速药物开发、2024年快速批准的见解等议题。